Intra-Hepatic Arterial Drug Delivery

References

• Allen-Mersh T G, Earlam S, Fordy C, Abrams K, Houghton J. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet (1994); 344: 1255–1260
   PubMed Web of Science ®Google Scholar
• Anderson J H, Kerr D J, Setanoians A, Cooke T G, McArdle C S. A pharmacokinetic comparison of intravenous versus intra-arterial folinic acid. Br J Cancer (1992a); 65: 133–135
   PubMed Web of Science ®Google Scholar
• Anderson J H, Kerr D J, Cooke T G, McArdle C S. A phase I study of regional 5-fluorouracil and systemic folinic acid for patients with colorectal liver metastases. Br J Cancer (1992b); 65: 913–915
   PubMed Web of Science ®Google Scholar
• Blesing C H, Julyan P J, Barnwell J M, Parker D J, Mountford P J, Kerr D J, Harding L K. Quantitative whole body counter biodistribution studies of 18F-5-fluorouracil following hepatic arterial and intravenous infusion. Br J Radiol (1995), Submitted for publication
   Google Scholar
• Campbell K A, Burns R C, Sitzmann J V, Lipsett P A, Grochow L B, Niederhuber J E. Regional chemotherapy devices: Effect of experience and anatomy on complications. J Clin Oncol (1993); 11: 822–826
   PubMed Web of Science ®Google Scholar
• Chang A E, Schneider P D, Sugarbaker P H, Simpson C, Culnane M, Steinberg S M. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg (1987); 206: 685–693
   PubMed Web of Science ®Google Scholar
• Chen H-S G, Gross J F. Intra-arterial infusion of anticancer drugs: Theoretic aspects of drug delivery and review of responses. Cancer Treat Rep (1980); 64: 31–40
   PubMedGoogle Scholar
• Collins J M. Pharmacologic rational for regional drug delivery. J Clin Oncol (1984); 2: 498–504
   PubMed Web of Science ®Google Scholar
• Cunningham V J, Pike V W, Bailey D, Freemantle C AJ, Page B C, Jones A KP, Kensett M J, Bateman D, Luthra S K, Jones T. A Method of studying pharmacokinetics in man at picomolar drug concentrations. Br J Clin Pharmac (1991); 32: 167–172
   PubMed Web of Science ®Google Scholar
• Dakhil S, Ensminger W, Cho K., Niederhuber J, Doan K, Wheeler R. Improved regional selectivity of hepatic arterial BCNU with degradable microspheres. Cancer (1982); 50: 631–635
   PubMed Web of Science ®Google Scholar
• de Takats P G, Kerr D J, Poole C J, Warren H W, McArdle C S. Hepatic arterial chemotherapy for metastatic colorectal carcinoma. Br J Cancer (1994); 69: 372–378
   PubMed Web of Science ®Google Scholar
• Dimitrakopoulou A, Strauss L G, Clorius J H, Ostertag H, Schlag P, Heim M, Oberdorfer F, Helus F, Haberkorn U, van Kaick G. Studies with positron emission tomography after systemic administration of fluorine-18-uracil in patients with liver metastases from colorectal carcinoma. J Nucl Med (1993); 34: 1075–1081
   PubMed Web of Science ®Google Scholar
• Dimitrakopoulou-Strauss A, Strauss L G, Schlag P, Helus F, Lorenz W J, Maier-Borst W, van Kaick G. Prediction of therapy outcome in patients with liver metastases from colorectal carcinoma. Eur J Nuc Med (1994); 21: 856
   Google Scholar
• Ensminger W D, Rosowsky A, Raso V, Levin D C, Glode M, Come S, Steele G, Frei E. A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2-deoxyuri-dine and 5-fluorouracil. Cancer Res (1978); 38: 3784–3792
   PubMed Web of Science ®Google Scholar
• Evans W E, Relling M V. Clinical pharmacokinetics-pharmacodynamics of anticancer drugs. Clin Pharmacokinetics (1989); 16: 327–336
   PubMed Web of Science ®Google Scholar
• Findlay M PN, Leach M O, Cunningham D, Collins D J, Payne G S, Glaholm J, Mansi J L, McCready J R. The noninvasive monitoring of low dose infusional 5-fluorouracil and its modulation by interferon-alpha using in vivo 19F magnetic resonance spactroscopy in patients with colorectal cancer: a pilot study. Ann Oncol (1993); 4: 597–602
   PubMed Web of Science ®Google Scholar
• Fortner J G, Silva J S, Golbey R B, Cox E B, Maclean B J. Multivariate analysis of a personal series of 247 consecutive patients with liver metastases from colorectal cancer. Ann Surg (1984); 199: 306–316
   PubMed Web of Science ®Google Scholar
• Frei E, Canellos G. Dose: A critical factor in cancer chemotherapy. Am J Med (1980); 69: 585–594
   PubMed Web of Science ®Google Scholar
• Goldberg J A, Kerr D J, Willmott N, McKillop J H, McArdle C S. Pharmacokinetics and pharmacodymamics of locoregional 5-fluorouracil (5-FU) in advanced colorectal liver metastases. Br J Cancer (1988); 57: 186–189
   PubMed Web of Science ®Google Scholar
• Goldberg J A, Kerr D J, Watson D G, Willmott N, Bates C D, McKillop J H, McArdle C S. The pharmacokinetics of 5-fluorouracil administered by arterial infusion in advanced colorectal hepatic metastases. Br J Cancer (1990a); 61: 913–915
   PubMed Web of Science ®Google Scholar
• Goldberg J A, Kerr D J, Willmott N, McKillop J H, McArdle C S. Regional chemotherapy for colorectal liver metastases: a phase II evaluation of targeted hepatic arterial 5-fluorouracil for colorectal liver metastases. Br j Surg (1990b); 77: 1238–1240
   PubMed Web of Science ®Google Scholar
• Goldberg JA, Murray T, Kerr D J, Willmott N, Bessent R G, McKillop J H, McArdle C S. The use of angiotensin II as a potential method of targeting cytotoxic microspheres in patients with intrahepatic tumour. Br J Cancer (1991a); 63: 308–310
   PubMed Web of Science ®Google Scholar
• Goldberg J A, Thomson J AK, Bradnam M S, Fenner J, Bessent R G, McKillop J H, Kerr D J, McArdle C S. Angiotensin II as a potential method of targeting cytotoxic-loaded microspheres in patients with colorectal liver metastases. Br J Cancer (1991b); 64: 114–119
   PubMed Web of Science ®Google Scholar
• Goldberg J A, Kerr D J, Blackie R, Whately T L, Pettit L, Kato T, McArdle C S. Mitomycin C loaded microcapsules in the treatment of colorectal liver metastases. Pharmacokinetics of regionally administered particulate chemotherapy. Cancer (1991c); 67: 952–955
   PubMed Web of Science ®Google Scholar
• Grage T B, Vassilopoulos P P, Shingleton W W, Jubert A V, Elias E G, Aust J B, Moss S E. Results of a prospective randomized study of hepatic artery infusion with 5-fluorouracil versus intravenous 5-fluorouracil in patients with hepatic metastases from colorectal cancer: A central oncology group study. Surgery (1979); 86: 550–555
   PubMed Web of Science ®Google Scholar
• Hohenberger P, Strauss L G, Lehner B, Frohmuller S, Dimitrakopoulou A, Schlag P. Perfusion of colorectal liver metastases and uptake of fluorouracil assessed by H2 15O and [18F] uracil positron emission tomography (PET). Eur J Cancer (1993); 29A: 1682–1686
   PubMed Web of Science ®Google Scholar
• Hohn D C, Stagg R J, Friedman M A, Hannigan J F, Rayner A, Ignoffo R J, Acord P, Lewis B J. A randomized trial of continuous intravenous versus hepatic intra arterial floxuridine in patients with colorectal cancer metastatic to the liver: The northern California oncology group trial. J Clin Oncol (1989); 7: 1646–1654
   PubMed Web of Science ®Google Scholar
• Hunt T M, Flowerdew A DS, Birch S J, Williams J D, Mullee M A, Taylor I. Prospective randomized controlled trial of hepatic arterial embolization or infusion chemotherapy with 5-fluorouracil and degradable starch microspheres for colorectal liver metastases. Br J Surg (1990); 77: 779–782
   PubMed Web of Science ®Google Scholar
• Jenkins S A, Day D W, Mooney B, Devitt P, Taylor I, Shields R. The effect of vasopressin and hepatic artery ligation on the blood supply to normal and metastatic liver tissue. Br J Cancer (1984); 50: 785–791
   PubMed Web of Science ®Google Scholar
• Kemeny N, Daly J, Reichman B, Geller N, Botet J, Oderman P. Intrahepatic or systemic infusion of fluorodeoxyuri-dine in patients with liver metastases from colorectal carcinoma. Ann Int Med (1987); 107: 459–465
   PubMed Web of Science ®Google Scholar
• Kemeny N, Niedzwiecki D, Shurgot B, Oderman P. Prognostic variables in patients with hepatic metastases from colorectal carcinoma. Cancer (1989); 63: 742–747
   PubMed Web of Science ®Google Scholar
• Kemeny N, Cohen A, Bertino J R, Sigurdson E R, Botet J, Oderman P. Continuous intrahepatic infusion of floxuridine and leucovorin through an implantable pump for the treatment of hepatic metastases from colorectal carcinoma. Cancer (1990); 65: 2446–2450
   PubMed Web of Science ®Google Scholar
• Kerr D J. 5-Fluorouracil and folinic acid: interesting biochemistry or effective treatment. Br J Cancer (1989); 60: 807–808
   PubMed Web of Science ®Google Scholar
• Kerr D J, Kaye S B. Chemoembolism in cancer therapy. Critical Reviews in Cancer (1991); 8: 19–39
   Google Scholar
• Kerr D J, Los G. Pharmacokinetic principles of locoregional chemotherapy. Cancer Surveys (1993); 17: 105–122
   PubMedGoogle Scholar
• Konno T, Maeda H, Iwai K, Tashiro S, Maki S, Morinaga T, Mochinaga M, Hiraoka T, Yokoyama I. Effect of arterial administration of high molecular weight anticancer agent SMANCS with lipid lymphography agent on hepatoma: a preliminary report. Eur J Clin Oncol (1983); 19: 1053–1065
   PubMedGoogle Scholar
• Lokich J J, Ahlgren J D, Gullo J J, Philips J A, Fryer J G. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A mid-Atlantic oncology programme study. J Clin Oncol (1989); 7: 425–432
   PubMed Web of Science ®Google Scholar
• Lotze M T, Flickinger J C, Carr B I. Hepatobiliary neoplasms. Cancer, Principles and Practice of oncology, VT De Vita, S Hellman, SA Rosenberg. JB Lippincott Co, Philadelphia, 883–914
   Google Scholar
• Martin J K, O'Connell M J, Wieand H S, Fitzgibbons R J, Mailliard J A, Rubin J, Nagorney D M, Tschetter L K, Krook J E. Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal carcinoma. A Randomized trial. Arch Surg (1990); 125: 1022–1027
   PubMed Web of Science ®Google Scholar
• Mayer R J. Chemotherapy for metastatic colorectal carcinoma. Cancer (1992); 70: 1414–1424
   PubMed Web of Science ®Google Scholar
• Niederhuber J E, Ensminger W, Gyves J, Thrall J, Walker S, Cozzi E. Regional chemotherapy of colorectal cancer metastatic to the liver. Cancer (1984); 53: 1336–1343
   PubMed Web of Science ®Google Scholar
• Peters G J, Lankelma J, Kok R M, Noordhuis P, van Groeningen C J, van der Wilt C L, Meyer S. Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumours as compared with plasma. Cancer Chemother Pharmacol (1993); 31: 269–276
   PubMed Web of Science ®Google Scholar
• Piedbois P, Buyse M, Rustum Y, Machover D, Erlichman C, Carlson R W, Valone F, Labianca R, Doroshow J H, Perrelli N. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol (1992); 10: 896–903
   PubMed Web of Science ®Google Scholar
• Present C A, Wolf W, Albright M J, Servis K L, Ring R, Atkinson D, Ong R L, Wiseman C, King M, Blayney D, Kennedy P, El-Tahtawy A, Singh M, Shani J. Human tumor fluorouracil trapping: Clinical correlations of in vivo 19F nuclear magnetic resonance spectroscopy pharmacokinetics. J Clin Oncol (1990); 8: 1868–1873
   PubMed Web of Science ®Google Scholar
• Present C A, Wolf W, Waluch V, Wiseman C, Kennedy P, Blayney D, Brechner R R. Association of intratumoral pharmacokinetics of fluorouracil with clinical response. Lancet (1994); 343: 1184–1187
   PubMed Web of Science ®Google Scholar
• Price P, Grifiths J. Tumour pharmacokinetics?—we do need to know. Lancet (1994); 343: 1174–1175
   PubMed Web of Science ®Google Scholar
• Rougier P, Ducreux M, Pignon J P, Elias D, Tigaud J M, Lumbroso J, Ruffie P, Lasser P H. Prognostic factors in patients with liver metastases from colorectal carcinoma treated with discontinuous intra-arterial hepatic chemotherapy. Eur J Cancer (1991); 27: 1226–1230
   PubMed Web of Science ®Google Scholar
• Rougier P, Laplanche A, Huguier M, Hay J M, Ollivier J M, Escat J, Salmon R, Julien M, Audy J CR, Gallot D, Gouzi J L, Pailler J L, Elisa D, Lacaine F, Roos S, Rotman N, Luboinski M, Lasser P. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: Long term results of a prospective randomized trial. J Clin Oncol (1992); 10: 1112–1118
   PubMed Web of Science ®Google Scholar
• Safi F, Bittner R, Roscher R, Schuhmacher K, Gaus W, Beger G H. Regional chemotherapy for hepatic metastases of colorectal carcinoma (continuous intraarterial versus continuous intraarterial/intravenous therapy. Cancer (1989); 64: 379–387
   PubMed Web of Science ®Google Scholar
• Sasaki Y, Imaoka S, Hasegawa Y, Nakano S, Ishikawa O, Ohigashi H, Taniguchi K, Koyama H, Iwanaga T, Terasawa T. Changes in distribution of hepatic blood flow induced by intra-arterial infusion of angiotensin II in human hepatic cancer. Cancer (1985); 55: 311–316
   PubMed Web of Science ®Google Scholar
• Schlemmer H P, Semmler W, Bachert P, Hohenberger P, Schlag P, van Kaick G. Evaluation of early response parameters for in vivo F-19 MR spectroscopy in therapy monitoring of patients with liver metastases of colorectal carcinoma. Radiology (1991); 181: 210
   Google Scholar
• Shepard K V, Levin B, Karl R C, Faintuch J, DuBrow R A, Hagle M, Cooper R M, Beschorner J, Stablein D. Therapy for metastatic colorectal carcinoma with hepatic artery infusion chemotherapy using a subcutaneous implanted pump. J Clin Oncol (1985); 3: 161–169
   PubMed Web of Science ®Google Scholar
• Stagg R J, Lewis B J, Friedman M A, Ignoffo R J, Hohn D C. Hepatic arterial chemotherapy for colorectal cancer metastatic to the liver. Ann Int Med (1984); 100: 736–743
   PubMed Web of Science ®Google Scholar
• Stevens A N, Morris P G, Iles RA, Sheldon P W, Griffiths J R. 5-Fluorouracil metabolism monitored in vivo by 19F NMR. Br I Cancer (1984); 50: 113–117
   PubMed Web of Science ®Google Scholar
• Strauss L G, Conti P S. The applications of PET in clinical oncolgy. J Nucl Med (1991); 32: 623–648
   PubMed Web of Science ®Google Scholar
• Sullivan R D, Norcross J W, Watkins E. Chemotherapy of metastatic liver cancer by prolonged hepatic artery infusion. N Engl I Med (1964); 270: 321–7
   PubMed Web of Science ®Google Scholar
• Wagner J S, Adson M A, van Heerden J A, Adson M H, Ilstrup D M. The natural history of hepatic metastases from colorectal carcinoma. Ann Surg (1984); 199: 502–508
   PubMed Web of Science ®Google Scholar
• Wagner J G, Gyves J W, Stetson P L, Walker-Andrews S C, Wollner I S, Cochran M K, Ensminger W D. Steady-state nonlinear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients. Cancer Res (1986); 46: 1499–1506
   PubMed Web of Science ®Google Scholar
• Warren H W, Anderson J H, O'Gorman P, Kane E, Kerr D J, Cooke T G, McArdle C S. A phase II study of regional 5-fluorouracil infusion with intravenous folinic acid for colorectal liver metastases. Br J Cancer (1994); 70: 677–680
   PubMed Web of Science ®Google Scholar
• Weiss L, Grundmann Torhorst J, Hartveit F, Moberg I, Eder M, Fenoglio-Preiser C M, Napier J, Home C HW, Lopez M J, Shaw-Dunn R I, Sugar J, Davis J D, Day D W, Harlos J P. Haematogenous metastatic patterns in colonic carcinoma: An anylsis of 1541 necropsies. J Pathol (1986); 150: 195–203
   PubMed Web of Science ®Google Scholar
• Wolf W, Presant C A, Servis K L, El-Tahtawy A, Albright M J, Barker P B, Ring R, Atkinson D, Ong R, King M, Singh M, Ray M, Wiseman C, Blayney D, Shani J. Tumor trapping of 5-fluorouracil: In vivo 19F NMR spectroscopic pharmacokinetics in tumor-bearing humans and rabbits. Proc Natl Acad Sci (1990); 87: 492–496
   PubMed Web of Science ®Google Scholar